Abstract
The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also known as protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital transduction cascade that is connected with many essential cellular activities, such as growth and survival. Along with extensive pharmacological studies validating the therapeutic potential of targeting the PI3K/Akt/mTOR pathway for the treatment of cancer, kinase inhibitors targeting significant knots of this pathway including PI3K, Akt, mTOR, and 3-phosphoinositide-dependent protein kinase-1 (PDK-1) keep arising and entering clinical studies. Herein, we review the most up-to-date landscape on developing small-molecule kinase inhibitors targeting the PI3K/Akt/mTOR pathway, with emphasis on small-molecule inhibitors which have been progressed into clinical studies.
Keywords: PI3K, Akt/PKB, mTOR, small-molecule inhibitor, clinical, cancer, PKB, Akt, PDK-1, cancer therapy, FDA, kinases, cell growth, proliferation, apoptosis, transcription, translation, migration, motility, angiogenesis, immunity, metabolism, FRAP1, Raptor, Rictor, Erlotinib, Sunitinib, Nilotinib, eIF, S6Ks, Mcl-1, SGK1, PKC, Rapamycin, CCI-779, RCC, SCCHN, RAD-001, OSI-027, AZD-8055, PI3K INHIBITORS, GPCRs, Vps34, PIKKs, ATM, ATR, DNA-PK, SMG-1, TRRAP, GDC-0941, xenografts, monotherapy, tumors, PX-866, BKM-120, CAL-101, malignancies, NHL, CLL, BGT226, MTD, XL-765, SF-1126, PI-103, PKA, PH, etoposide, perifosine, TCN-PM, triciribine phosphate, mutation, AGC, ATP, COX2, UCN-01, Celecoxib
Current Medicinal Chemistry
Title: PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Volume: 17 Issue: 35
Author(s): P. Wu and Y.-Z. Hu
Affiliation:
Keywords: PI3K, Akt/PKB, mTOR, small-molecule inhibitor, clinical, cancer, PKB, Akt, PDK-1, cancer therapy, FDA, kinases, cell growth, proliferation, apoptosis, transcription, translation, migration, motility, angiogenesis, immunity, metabolism, FRAP1, Raptor, Rictor, Erlotinib, Sunitinib, Nilotinib, eIF, S6Ks, Mcl-1, SGK1, PKC, Rapamycin, CCI-779, RCC, SCCHN, RAD-001, OSI-027, AZD-8055, PI3K INHIBITORS, GPCRs, Vps34, PIKKs, ATM, ATR, DNA-PK, SMG-1, TRRAP, GDC-0941, xenografts, monotherapy, tumors, PX-866, BKM-120, CAL-101, malignancies, NHL, CLL, BGT226, MTD, XL-765, SF-1126, PI-103, PKA, PH, etoposide, perifosine, TCN-PM, triciribine phosphate, mutation, AGC, ATP, COX2, UCN-01, Celecoxib
Abstract: The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also known as protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital transduction cascade that is connected with many essential cellular activities, such as growth and survival. Along with extensive pharmacological studies validating the therapeutic potential of targeting the PI3K/Akt/mTOR pathway for the treatment of cancer, kinase inhibitors targeting significant knots of this pathway including PI3K, Akt, mTOR, and 3-phosphoinositide-dependent protein kinase-1 (PDK-1) keep arising and entering clinical studies. Herein, we review the most up-to-date landscape on developing small-molecule kinase inhibitors targeting the PI3K/Akt/mTOR pathway, with emphasis on small-molecule inhibitors which have been progressed into clinical studies.
Export Options
About this article
Cite this article as:
Wu P. and Hu Y.-Z., PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress, Current Medicinal Chemistry 2010; 17 (35) . https://dx.doi.org/10.2174/092986710793361234
DOI https://dx.doi.org/10.2174/092986710793361234 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fc-fusion Proteins in Therapy: An Updated View
Current Medicinal Chemistry Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview
Mini-Reviews in Medicinal Chemistry Polysaccharide Based Formulations for Mucosal Drug Delivery: A Review
Current Pharmaceutical Design Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design microRNAs: Small Molecules with a Potentially Role in Oral Squamous Cell Carcinoma
Current Pharmaceutical Design Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Biofunctional Materials for Directing Vascular Development
Current Vascular Pharmacology Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
Current Cancer Drug Targets Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design